TLX vs TRNI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TLX Captures Institutional Edge (2โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Telix Pharmaceuticals Limited American Depositary Shares (TLX) driven by superior Valuation, Growth & Margin while TRNI counters with relative strength in Momentum & Technical. Fundamentally, TLX trades at N/M Forward P/E with 6.2% operating margin (+22.3% YoY revenue) versus TRNI at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, TLX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against TRNI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TLX | TRNI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | N/A | Larger Scale | TLX |
| Trailing P/E Ratio Valuation | 87.1x | N/M | Lower Multiple | TLX |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +22.3% | N/A | Higher Growth | TLX |
| Operating Margin (TTM) Profitability | 6.2% | N/A | Higher Margin | TLX |
| Net Profit Margin Profitability | 3.8% | N/A | Higher Margin | TLX |
| Return on Equity (ROE) Capital Efficiency | 7.4% | N/A | Higher ROE | TLX |
| 52-Week Range Position Momentum | 31% ($6โ$13) | 25% ($25โ$25) | Stronger Trend | TLX |
| Beta / 30D Volatility Risk Regime | 0.91ฮฒ ยท 48% Vol | 0.03ฮฒ ยท 3% Vol | Lower Realized Risk | TRNI |
| Unified Institutional Score Composite Signal | 37.6 / 100 (SELL) | 44.3 / 100 (HOLD) | Higher Composite | TRNI |